Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$18.02 +6.3%	$21.58	$15.47 ▼ $36.37	$687.64M	1.17	281,266 shs	543,062 shs
DERM Journey Medical	$7.25 -15.1%	$7.16	$3.54 ▼ $8.90	$198.95M	0.8	148,083 shs	484,841 shs
FBIO Fortress Biotech	$1.93 -4.0%	$1.90	$1.33 ▼ $2.36	$59.44M	1.76	173,085 shs	236,916 shs
MNMD Mind Medicine (MindMed)	$9.97 -1.8%	$8.22	$4.70 ▼ $10.49	$772.29M	2.49	1.32 million shs	1.04 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-2.70%	-12.85%	-21.64%	-9.60%	-24.33%
DERM Journey Medical	+8.51%	+18.45%	+19.44%	+43.05%	+101.42%
FBIO Fortress Biotech	+4.69%	+5.51%	+6.35%	+21.08%	+13.56%
MNMD Mind Medicine (MindMed)	+1.50%	+5.29%	+25.93%	+55.20%	+48.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.9074 of 5 stars	4.6	0.0	1.7	0.8	0.0
DERM Journey Medical	1.6537 of 5 stars	3.5	1.0	1.6	0.8	0.6
FBIO Fortress Biotech	2.6176 of 5 stars	3.5	1.0	2.4	3.3	0.6
MNMD Mind Medicine (MindMed)	2.0903 of 5 stars	3.6	1.0	2.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.14	117.22% Upside
DERM Journey Medical	3.00	Buy	$10.83	49.43% Upside
FBIO Fortress Biotech	3.00	Buy	$21.00	988.08% Upside
MNMD Mind Medicine (MindMed)	3.22	Buy	$24.71	147.89% Upside

Current Analyst Ratings Breakdown

Latest DERM, FBIO, AVBP, and MNMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	DERM Journey Medical	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $13.00
8/12/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $42.00
8/12/2025	AVBP ArriVent BioPharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $33.00
8/4/2025	MNMD Mind Medicine (MindMed)	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$25.00
8/1/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/22/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
7/10/2025	AVBP ArriVent BioPharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$33.00
6/24/2025	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$39.00 ➝ $44.00
6/24/2025	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/15/2025	DERM Journey Medical	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$6.16 per share	N/A
DERM Journey Medical	$56.13M	3.01	N/A	N/A	$0.91 per share	7.97
FBIO Fortress Biotech	$57.67M	0.99	N/A	N/A	($0.06) per share	-32.17
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$2.44 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$80.49M	-$3.77	N/A	N/A	N/A	N/A	-55.40%	-51.97%	8/13/2025 (Estimated)
DERM Journey Medical	-$14.67M	-$0.39	N/A	N/A	N/A	-15.49%	-49.90%	-11.44%	N/A
FBIO Fortress Biotech	-$46M	-$2.23	N/A	N/A	N/A	-71.24%	-4,712.53%	-27.67%	N/A
MNMD Mind Medicine (MindMed)	-$108.68M	-$1.53	N/A	N/A	N/A	N/A	-50.24%	-39.41%	N/A

Latest DERM, FBIO, AVBP, and MNMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	DERM Journey Medical	-$0.07	-$0.16	-$0.09	-$0.16	$14.93 million	$15.01 million
8/11/2025	Q2 2025	AVBP ArriVent BioPharma	-$0.70	-$0.90	-$0.20	-$0.90	N/A	N/A
7/31/2025	Q2 2025	MNMD Mind Medicine (MindMed)	-$0.38	-$0.50	-$0.12	-$0.50	N/A	N/A
5/14/2025	Q1 2025	DERM Journey Medical	-$0.24	-$0.18	+$0.06	-$0.18	$12.05 million	$13.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	12.74	14.34
DERM Journey Medical	1.07	1.34	1.03
FBIO Fortress Biotech	1.74	1.72	1.55
MNMD Mind Medicine (MindMed)	0.22	4.98	4.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
DERM Journey Medical	7.25%
FBIO Fortress Biotech	96.51%
MNMD Mind Medicine (MindMed)	27.91%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
DERM Journey Medical	15.03%
FBIO Fortress Biotech	27.90%
MNMD Mind Medicine (MindMed)	2.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	40.57 million	27.86 million	N/A
DERM Journey Medical	90	23.30 million	19.80 million	N/A
FBIO Fortress Biotech	170	29.57 million	21.32 million	Optionable
MNMD Mind Medicine (MindMed)	40	76.09 million	74.22 million	Optionable

DERM, FBIO, AVBP, and MNMD Headlines

Recent News About These Companies

Mind Medicine (MindMed) (NASDAQ:MNMD) Hits New 52-Week High - Here's What Happened

August 13 at 2:38 PM | marketbeat.com

If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today

August 12 at 5:00 AM | fool.com

Could This Psychedelic Drug Stock Be a Top Buy for 2026?

August 8, 2025 | msn.com

Could This Psychedelic Drug Stock Be a Top Buy for 2026?

August 8, 2025 | msn.com

Research Analysts Issue Forecasts for MNMD Q3 Earnings

August 8, 2025 | americanbankingnews.com

HC Wainwright Has Negative Outlook for MNMD Q3 Earnings

August 7, 2025 | marketbeat.com

Roth Capital Brokers Reduce Earnings Estimates for MNMD

August 7, 2025 | marketbeat.com

1 Reason to Buy MindMed (MNMD)

August 7, 2025 | fool.com

HC Wainwright Has Positive Estimate for MNMD FY2028 Earnings

August 7, 2025 | americanbankingnews.com

Mind Medicine (MindMed) (NASDAQ:MNMD) Research Coverage Started at Oppenheimer

August 7, 2025 | americanbankingnews.com

Roth Capital Issues Pessimistic Forecast for MNMD Earnings

August 7, 2025 | americanbankingnews.com

FY2028 Earnings Estimate for MNMD Issued By HC Wainwright

August 6, 2025 | marketbeat.com

Is Mind Medicine stock a buy?

August 6, 2025 | cantechletter.comC

Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 10.9% - Time to Buy?

August 5, 2025 | marketbeat.com

Mind Medicine (MindMed) (NASDAQ:MNMD) Now Covered by Oppenheimer

August 5, 2025 | marketbeat.com

Mind Medicine (MindMed) (NASDAQ:MNMD) Issues Earnings Results

August 3, 2025 | marketbeat.com

Mind Medicine (MindMed) (NASDAQ:MNMD) Given Buy Rating at Chardan Capital

August 2, 2025 | marketbeat.com

MindMed (MNMD) Q2 Net Loss Jumps 625%

August 1, 2025 | fool.com

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

July 31, 2025 | seekingalpha.com

MindMed Reports Q2 2025 Financial Results and Business Updates

July 31, 2025 | businesswire.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Average Recommendation of "Buy" by Analysts

July 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM, FBIO, AVBP, and MNMD Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$18.02 +1.07 (+6.31%)

Closing price 04:00 PM Eastern

Extended Trading

$18.00 -0.02 (-0.11%)

As of 05:24 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Journey Medical NASDAQ:DERM

$7.25 -1.29 (-15.11%)

Closing price 04:00 PM Eastern

Extended Trading

$7.80 +0.56 (+7.66%)

As of 07:59 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Fortress Biotech NASDAQ:FBIO

$1.93 -0.08 (-3.98%)

Closing price 04:00 PM Eastern

Extended Trading

$1.96 +0.03 (+1.55%)

As of 07:44 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Mind Medicine (MindMed) NASDAQ:MNMD

$9.97 -0.18 (-1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$9.99 +0.02 (+0.24%)

As of 07:59 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time